<DOC>
	<DOCNO>NCT02121210</DOCNO>
	<brief_summary>Primary Objective : To evaluate immunogenicity sarilumab administer monotherapy . Secondary Objectives : - To evaluate safety aspect sarilumab administer monotherapy . - To assess exposure sarilumab administer monotherapy .</brief_summary>
	<brief_title>To Evaluate Immunogenicity Safety Sarilumab Administered Monotherapy Patients With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description>Total study duration 34 week : Up 4-week screening period , 24-week open-label treatment phase , 6-week post-treatment observation . After completion treatment phase study , patient eligible enter long term safety study ( LTS11210 - SARIL-RA-EXTEND ) continuous treatment sarilumab ( SAR153191 [ REGN88 ] ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Inclusion criterion : Diagnosis rheumatoid arthritis ( RA ) â‰¥ 3 month . Moderately severely active rheumatoid arthritis . Patients per investigator judgment incomplete responder least 12 week adequate dose continuous treatment intolerant one combination nonbiologic disease modify antirheumatic drug ( DMARDs ) . Exclusion criterion : Patients &lt; 18 year age . Past history , current , autoimmune inflammatory systemic localize joint disease ( ) RA . History juvenile idiopathic arthritis arthritis onset prior age 16 . Severe active systemic RA , include limited vasculitis , pulmonary fibrosis , and/or Felty 's syndrome . Prior treatment biologic antiinterleukin 6 ( IL6 ) IL6 receptor ( IL6R ) antagonist therapy . Treatment prednisone &gt; 10 mg equivalent per day , change dosage within 4 week prior randomization . New treatment doseadjustment ongoing nonsteroidal antiinflammatory drug ( NSAIDs ) cyclooxygenase2 ( COX2 ) inhibitor within 4 week prior randomization , except use lowdose acetylsalicylic acid cardiovascular disease . Use parenteral glucocorticoid intraarticular glucocorticoid injection within 4 week prior randomization . Prior treatment Janus kinase ( JAK ) inhibitor ( tofacitinib ) . New treatment doseadjustment ongoing medication dyslipidemia , statin , within 6 week prior randomization . Participation clinical research study evaluate another investigational drug therapy within 5 halflives 60 day first dose study drug administration , whichever longer . Patients history malignancy adequatelytreated carcinoma insitu cervix , nonmetastatic squamous cell basal cell carcinoma skin , within 5 year prior randomization visit . Nonmalignant lymphoproliferative disorder also exclude . Patients active tuberculosis untreated latent tuberculosis infection . Pregnant breast feed woman . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>